Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz Sells 77,853 Shares

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 77,853 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $50.09, for a total transaction of $3,899,656.77. Following the transaction, the chief executive officer now directly owns 2,069,456 shares in the company, valued at $103,659,051.04. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The shares were sold at an average price of $50.07, for a total transaction of $1,990,332.57.
• On Thursday, June 5th, Amirali Talasaz sold 1,680 shares of Guardant Health stock. The shares were sold at an average price of $50.00, for a total transaction of $84,000.00.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84.

Guardant Health Trading Up 3.1%

Shares of NASDAQ GH traded up $1.47 during midday trading on Monday, hitting $49.53. The company's stock had a trading volume of 2,926,769 shares, compared to its average volume of 2,130,739. The stock has a fifty day moving average price of $43.05 and a 200 day moving average price of $41.25. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $52.92. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of -13.91 and a beta of 1.37.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. The company's quarterly revenue was up 20.8% compared to the same quarter last year. On average, equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. TD Securities raised their price target on shares of Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Barclays lifted their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, May 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $60.00 price objective (up previously from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Finally, Stephens reaffirmed an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $53.29.

Hedge Funds Weigh In On Guardant Health

Hedge funds have recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in Guardant Health during the first quarter valued at approximately $54,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman & Baird LLC purchased a new position in Guardant Health during the fourth quarter valued at approximately $58,000. NewEdge Advisors LLC grew its stake in Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health during the fourth quarter valued at approximately $61,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.